CBL-B (Human) CRISPR/Cas9 Lentivirus (Non-Integrating)

Catalog #

78344

$995 *

Size: 500 µl x 2

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

CBL-B is an E3 ubiquitin-protein ligase which has been identified as a negative regulator of T-cell activation. Using CRISPR/Cas9 to inactivate CBL-B has been shown to be sufficient to inhibit T-cell expansion.

The CBL-B CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1A promoter, along with 5 sgRNA (single guide RNAs) targeting human CBL-B driven by a U6 promoter (Figures 1 and 2).

Note: unlike CBL-B CRISPR/Cas9 Lentivirus (Integrating) (BPS Bioscience, #78343), the CBL-B CRISPR/Cas9 Lentivirus (Non-Integrating) is made with a mutated Integrase, resulting in only transient expression of the Cas9 and CBL-B-targeting sgRNA. It is expected that this will minimize potential off-target effects caused by either prolonged expression or random integration of Cas9 and the sgRNA. A short round of puromycin selection right after transduction may increase knockout efficiency, however puromycin should not be used for more than 48 hours post-transduction due to the transient nature of expression using the non-integrating lentivirus.

Figure 1. Schematic of the Lenti-vector used to generate the CBL-B CRISPR/Cas9 Lentivirus

Gene Target:	sgRNA Sequence
CBL-B	TGTGGGATGTCGACTCCTAG
CBL-B	CTTCATCTCTTGGATCAAAG
CBL-B	TTCCGCAAAATAGAGCCCCA
CBL-B	TGAATTAGATCCAGGCGAGG
CBL-B	TGCACAGAACTATCGTACCA

Figure 2. List of sgRNA Sequences in the CBL-B CRISPR/Cas9 Lentivirus

●

Synonyms

CBL-B, CBLB, Cbl proto-oncogene B, RING finger protein 56, RNF56, Nbla00127, E3 ubiquitin-protein ligase CBL-B, Casitas B-lineage lymphoma proto-oncogene b

●

Product Data Gallery

Product Info

Storage and Usage

Citations

Species

Replication Incompetent HIV

Supplied As

Two vials (500 µl x 2) of lentivirus at a titer ≥1 x 10⁶ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

Formulation

The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.

Storage/Stability

Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the lentiviruses at -80°C.

Applications

1. Transient knock-down of CBL-B in target cells
2. Generation of stable CBL-B knock-out cells using transient puromycin selection (48h maximum) followed by limited dilution.

Shipping Temperature

-80°C

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

Troubleshooting Guide
Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Biosafety
None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Scientific Category

CRISPR

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

CBL-B (Human) CRISPR/Cas9 Lentivirus (Non-Integrating)

PRODUCTS

SERVICES

RESOURCES

COMPANY